Site Editor

Thomas Flaig, MD

Advertisement

Advertisement

Medical Literature

Treatment Patterns and Outcomes in Muscle-Invasive Bladder Cancer

News

Update From EV-103: Enfortumab Vedotin-ejfv Plus Pembrolizumab for Advanced Urothelial Carcinoma

JNCCN Spotlights

Sacituzumab Govitecan-hziy

Medical Literature

Adjuvant Nivolumab for Patients With High-Risk Muscle-Invasive Urothelial Carcinoma

News

Enfortumab Vedotin-ejfv Receives FDA Approval for Advanced Urothelial Carcinoma

Medical Literature

Adjuvant Nivolumab for Patients With High-Risk Muscle-Invasive Urothelial Carcinoma

JNCCN Spotlights

Sacituzumab Govitecan-hziy

Aristotelis Bamias, MD, PhD, on Urothelial Carcinoma: Atezolizumab and Platinum-Based Chemotherapy

Enrique Grande, MD, PhD, on Results From IMvigor130: Atezolizumab Plus Platinum-Based Chemotherapy for Urothelial Cancer

View More

Advertisement

JNCCN Spotlights

Enfortumab Vedotin-ejfv

Sacituzumab Govitecan-hziy

View More

More

News

ASCO 2021: INDUCE-1 Trial of Feladilimab Plus Pembrolizumab in Urothelial Carcinoma

Can Circulating Tumor Cells Predict Need for Neoadjuvant Chemotherapy in Bladder Cancer?

Update on Potential Biomarkers for Predicting Bladder Cancer Lymph Node Metastasis

Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: Changing the Treatment Game

ASCO 2021: 5-Year Update on Pembrolizumab for Advanced Urothelial Cancer

ASCO 2021: Bladder-Sparing Combination Therapy Under Study in Muscle-Invasive Urothelial Cancer

Long-Term Outcomes and Costs of BCG Therapy for High-Risk Non–Muscle-Invasive Bladder Cancer

ASCO 2021: KEYNOTE-052 Survival Update on First-Line Pembrolizumab in Advanced Urothelial Cancer

View More

Advertisement

Published

Medical Literature

Combination Regimen Under Study in Metastatic Urothelial Carcinoma

Update on Managing Non–Muscle-Invasive Bladder Cancer

Can Leukocyte Telomere Length Predict Bladder Cancer Risk?

Bladder Urothelial Carcinoma: Is Age Related to Risk of Lymph Node Metastasis?

View More

Ongoing

CE Activities

Metastatic Urothelial Carcinoma: 2020 Multidisciplinary Molecular Tumor Board

Newly Approved Agents for Patients with Metastatic Urothelial Bladder Carcinoma Who Experience Disease Progression on Immune Checkpoint Inhibitor Therapy

Oncology Today with Dr Neil Love: Immune Checkpoint Inhibitors in Urothelial Bladder Carcinoma

Emerging Paradigms in Advanced/Metastatic Urothelial Cancer: What Are the Implications to Practice?

View More

Available

Clinical Trials

Early Intervention for Impairments Identified During Comprehensive Geriatric Assessment in Patients With Bladder Cancer

Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer

Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer

Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation

View More

Resources

For Your Patients

Bladder Cancer Advocacy Network

American Cancer Society

American Bladder Cancer Society

JNCCN: How To Manage Cancer Care During COVID-19 Pandemic

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2021 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.